Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated cirrhosis (F4) due to NASH. Selonsertib has been tested in another study (STELLAR-3) in an earlier stage (F3) of NASH, where it has now been announced that also here, selonsertib failed to meet the primary endpoint of […]